1. Record Nr. UNINA9910683374303321

Titolo	Novel therapeutic considerations in bone and soft tissue sarcoma / / Dimosthenis Andreou, Joanna Szkandera [editors]
Pubbl/distr/stampa	Basel : , : MDPI, , [2023] ©2023
ISBN	3-0365-7014-4
Descrizione fisica	1 online resource
Disciplina	616.994059
Soggetti	Sarcoma - Surgery
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Preface to "Novel Therapeutic Considerations in Bone and Soft Tissue Sarcoma" vii -- Alexander Klein, Theresa Fell, Christof Birkenmaier, Julian Fromm, Volkmar Jansson and -- Thomas Kn ¨osel et al. -- Relative Sensitivity of Core-Needle Biopsy and Incisional Biopsy in the Diagnosis of -- Musculoskeletal Sarcomas -- Reprinted from: Cancers 2021, 13, 1393, doi:10.3390/cancers13061393 1 -- Zeger Rijs, A. Naweed Shifai, Sarah E. Bosma, Peter J. K. Kuppen, Alexander L. Vahrmeijer -- and Stijn Keereweer et al. -- Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue -- Sarcomas: A Systematic Review -- Reprinted from: Cancers 2021, 13, 557, doi:10.3390/cancers13030557 11 -- Mateusz Jacek Spaek, Aneta Maria Borkowska, Maria Telejko, Micha Wagrodzki, Daria -- Niebyowska and Aldona Uzar et al. -- The Feasibility Study of Hypofractionated Radiotherapy with Regional Hyperthermia in Soft -- Tissue Sarcomas -- Reprinted from: Cancers 2021, 13, 1332, doi: 10.3390/cancers13061332 39 -- Christoph Theil, Kristian Nikolaus Schneider, Georg Gosheger, Ralf Dieckmann, Niklas -- Deventer and Jendrik Hardes et al. -- Does the Duration of Primary and First Revision Surgery Influence the Probability -- of First and Subsequent Implant Failures after Extremity Sarcoma Resection and -- Megaprosthetic Reconstruction? -- Reprinted from: Cancers 2021, 13, 2510, doi: 10.3390/cancers13112510 53 -- Richard E. Evenhuis, Ibtissam Acem, Anja J. Rueten-Budde, Diederik S. A. Karis, Marta -- Fiocco and Desiree

M. J. Dorleijn et al. -- Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with -- Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center -- Reprinted from: Cancers 2021, 13, 486, doi:10.3390 /cancers13030486 63 -- Daniel Pink, Dimosthenis Andreou, Sebastian Bauer, Thomas Brodowicz, Bernd Kasper and -- Peter Reichardt et al. -- Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA -- (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary -- Sarcoma Group (GISG-06) -- Reprinted from: Cancers 2021, 13, 1223, doi:10.3390/cancers13061223 77 -- Andrea P. Espejo-Freire, Andrew Elliott, Andrew Rosenberg, Philippos Apolinario Costa, -- Priscila Barreto-Coelho and Emily Jonczak et al. -- Genomic Landscape of Angiosarcoma: A Targeted and Immunotherapy Biomarker Analysis -- Reprinted from: Cancers 2021, 13, 4816, doi: 10.3390/cancers13194816 87 -- Luana Madalena Sousa, Jani Sofia Almeida, T ˆania Fortes-Andrade, Manuel Santos-Rosa, -- Paulo Freitas-Tavares and Jos´e Manuel Casanova et al. -- Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy -- Reprinted from: Cancers 2021, 13, 3885, doi: 10.3390/cancers13153885 101 -- Gemma Di Pompo, Margherita Cortini, Nicola Baldini and Sofia Avnet -- Acid Microenvironment in Bone Sarcomas -- Reprinted from: Cancers 2021, 13, 3848, doi: 10.3390/cancers13153848 123 -- Georgia Karpathiou, Maroa Dridi, Lila Krebs-Drouot, Fran¸cois Vassal, Emmanuel Jouanneau -- and Timoth ´ee Jacquesson et al. -- Autophagic Markers in Chordomas: Immunohistochemical Analysis and Comparison with the -- Immune Microenvironment of Chordoma Tissues -- Reprinted from: Cancers 2021, 13, 2169, doi:10.3390/cancers13092169 -- 145.

Sommario/riassunto

Sarcomas are a group of rare cancers that arise in connective tissues of the body. Surgical resection is pivotal for the management of locoregional disease. In locally advanced or metastatic disease settings, systemic therapy has an important role in the multidisciplinary management of sarcoma. Cytotoxic therapy has been the primary treatment for many years. However, recent advances in molecular pathogenesis, the investigation of the tumour microenvironment, changes in clinical trial design, and increased international collaboration have led to the development of histology-driven therapy. Furthermore, genomic profiling has highlighted that, while some sarcomas have complex karyotypes, others are driven by translocation, amplification, and mutation, representing targets for the development of novel therapies. Checkpoint inhibitors have been used as single agents or in combination in clinical sarcoma trials. This progress will move the therapeutic modality in sarcoma patients from the "one-size-fits-all" approach towards a more personalized therapeutic algorithm and better outcomes soon. In this Special Issue, we present original research and review articles highlighting novel therapeutic approaches in the treatment of sarcoma patients.